We greatly appreciate Dr. Murphy’s continuing support and guidance in Bioheart’s scientific and business endeavors,” stated Mike Tomas, Bioheart’s President and Chief Executive Officer. Dr. Murphy’s experience and commitment to the Company is a key component of our success. As we advance through our turn-around milestones we look forward to rewarding Dr. Murphy for his financial commitments through continuing increases in the value of Bioheart’s stock price.
News 
Market Data 
Discover 
